Price$4.44-2.38 (-34.85%)
2026-05-212026-08-25
News · 26 weeks60+1700%
2026-03-012026-08-23
Mix2490d
- Insider12(50%)
- Other7(29%)
- SEC Filings4(17%)
- Offering1(4%)
Latest news
25 items- PRPresenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live streamMIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter All times are in Eastern Time Presenting Today – Wednesday August 19, 2026 8:30Virtual Lobby opens.Register for the Con
- PRPresenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live streamMIAMI, Aug. 18, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter All times are in Eastern Time Day 1 - WednesdayAugust 19, 2026 8:30Virtual Lobby opens.Register for the Conference. I
- PRClene to Present at the Emerging Growth ConferenceSALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: August 19, 2026Time of Presentation: 3:10 p.m. ETFormat: Corporate update A webcast of the presentation will be available on the "Events" section of the Clene website. Alternatively, one can register for and view the webcast here: https://goto.webcasts.com/starthere.jsp?ei=1764701&tp_key=7a35454f76&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event. Abo
- INSIDERSEC Form 4 filed by Director Kiernan Matthew4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Desai Arjun Jj4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Mosca Alison4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Matlin David J4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Jacobovitz Shalom4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Gay Jonathon4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Mclaughlin Vallerie4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Wilcox Reed N4 - Clene Inc. (0001822791) (Issuer)
- SECClene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Clene Inc. (0001822791) (Filer)
- PRClene Reports Second Quarter 2026 Financial Results and Recent Operating HighlightsClene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026Clene announces survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized SALT LAKE CITY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) today announced its second quarter 2026 financial results and provided recent updates on its CNM-Au8 programs. "We plan to submit our new drug application (NDA) for CNM-Au8 under the accelerated approval pathway for patients with ALS and believe the evidence connecting the magnitude of NfL reduction to clinical benefit data we have generated since our last FDA meeting will
- SECSEC Form 10-Q filed by Clene Inc.10-Q - Clene Inc. (0001822791) (Filer)
- SECClene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Clene Inc. (0001822791) (Filer)
- PRClene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated ApprovalSurvival benefit is concentrated in participants with NfL biomarker response: CNM-Au8®-treated patients whose NfL declined or stabilized lived significantly longer than concurrently randomized controlsFunctional benefit concentrated in participants with NfL biomarker response: CNM-Au8-treated patients whose NfL declined or stabilized had significantly better outcomes on combined measures of survival and function, including daily function (ALSFRS-R) and breathing capacity (Slow Vital Capacity), than concurrently randomized controls SALT LAKE CITY, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) today announced results from new analyses examining clinical outcomes among CNM-Au8®-
- INSIDERSEC Form 4 filed by Large owner Ugwumba Chidozie4 - Clene Inc. (0001822791) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Clene Inc.SCHEDULE 13G - Clene Inc. (0001822791) (Subject)
- PRClene to Present at The Canaccord 46th Annual Growth ConferenceSALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 46th Annual Growth Conference and host 1x1 investor meetings. Date: August 11, 2026Time of Presentation: 10:30am ETLocation: Boston, MA A webcast of the presentation will be available on the "Events" section of the Clene website. Alternatively, one can register online
- PRNovel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple SclerosisAUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate
- INSIDERSEC Form 4 filed by Chief Science Officer Mortenson Mark4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Etherington Robert Dee4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Brown Morgan R4 - Clene Inc. (0001822791) (Issuer)
- SECSEC Form S-8 filed by Clene Inc.S-8 - Clene Inc. (0001822791) (Filer)
- SECSEC Form SD filed by Clene Inc.SD - Clene Inc. (0001822791) (Filer)
CLNN FAQ
6 questionsWhat does Clene Inc. do?
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative...Where does CLNN stock trade?
Clene Inc. (CLNN) is listed on NASDAQ.What sector and industry is CLNN in?
Clene Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CLNN?
Clene Inc. has had 4 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2022-10-04. Recent price targets range from $1000.00 to $2000.00.What companies are similar to CLNN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CLNN side-by-side with any of them on Quantisnow.How can I track CLNN on Quantisnow?
Quantisnow aggregates Clene Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLNN to receive live email and push alerts on every new disclosure.